Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. USANA Health Sciences
  4. Financial Ratios
USANA Health Sciences logo
USANA Health Sciences USNA
$ 14.22 -3.4%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

USANA Health Sciences Financial Ratios 2026-2009 | USNA

Brief overview of USANA Health Sciences's multiples and efficiency

The review covers five available annual periods spanning 2021 to 2026.

Market valuation is represented by P/E 30.21x (median 16.96x), EV/EBITDA 4.62x (median 6.96x), P/S 0.35x (median 1.01x). Multiples are on average 33.6% below their own medians. Shares look cheaper than their recent historical valuation.

The 1/P/E calculation produces a 3.3% earnings yield. It does not capture future growth or capital structure.

Returns on assets and capital are represented by ROE 2%, ROA 1.4%, ROCE 7%. Profitability remains low. Market valuation has limited fundamental support until resource returns improve.

Current PEG is 0.22x; the market pays comparatively little per unit of expected growth.

The time from paying for inputs to receiving cash rose from 62.9 days to 77.5 days. Cash turnover slowed.

Overall assessment

USANA Health Sciences's discount may reflect genuine profitability issues rather than market inefficiency alone.

Annual Financial Ratios USANA Health Sciences

2026 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

P/E

 30.2 8.0 14.6 17.0 17.2 - 15.2 22.4 29.9 18.3 18.0 - 10.7 8.3 13.2 8.1 -

P/S

 0.4 0.4 1.0 1.2 1.9 - 1.4 2.4 1.8 1.9 1.7 - 1.2 0.8 1.2 - -

EPS

 0.6 2.2 3.3 3.6 5.9 - 4.4 5.2 2.6 4.1 2.9 - 5.8 4.6 3.3 2.2 -

EV (Enterprise Value)

 323 M 315 M 736 M 888 M 1.83 B - 1.46 B 2.77 B 1.78 B 1.7 B 1.38 B - 812 M 562 M 624 M 259 M -13.3 M

EBITDA per Share

 3.78 4.23 5.49 6.28 8.99 - 7.05 8.33 6.01 5.75 4.56 - 4.43 3.59 2.39 3.77 -

EV/EBITDA

 4.6 3.9 7.0 7.3 9.6 - 8.0 12.7 10.9 10.5 10.1 - 5.6 4.5 7.6 4.5 -

PEG

 - - - - - - -1.08 0.22 -0.78 0.64 35.86 - 0.43 0.27 0.42 - -

P/B

 0.6 0.6 1.9 2.0 3.3 - 4.3 7.2 5.1 6.2 6.0 - 3.2 3.0 4.1 - -

P/CF

 14.5 5.5 13.2 11.3 13.3 - 13.8 20.1 16.9 19.7 16.2 - 9.3 6.5 9.8 8.4 -

ROE %

 2.02 7.90 12.83 15.96 28.23 - 28.58 32.27 17.22 33.71 33.28 - 30.33 35.78 31.13 45.12 -

ROA %

 1.45 5.62 10.08 11.63 19.45 - 19.45 22.77 12.04 22.37 21.85 - 21.44 24.83 21.10 - -

ROCE %

 7.02 12.46 18.72 24.77 39.96 - 38.39 46.42 35.05 48.54 48.00 - 42.81 49.95 43.27 68.29 -

Current Ratio

 4.7 4.6 4.7 - - - 2.4 2.6 2.4 1.9 1.8 - 2.4 1.9 1.4 - -

DSO

 - - - - - - 3.6 4.9 5.7 6.0 7.6 - 9.7 7.9 8.3 - -

DIO

 93.2 148.5 132.8 148.1 78.7 - 134.1 149.0 128.0 151.1 117.2 - 135.2 115.0 130.3 - -

DPO

 15.7 25.0 21.8 27.5 15.9 - 24.4 18.1 24.0 23.0 20.2 - 27.2 22.1 24.5 - -

Operating Cycle

 93.2 148.5 132.8 148.1 78.7 - 137.7 154.0 133.7 157.1 124.8 - 144.9 122.9 138.6 - -

Cash Conversion Cycle

 77.5 123.5 111.0 120.5 62.9 - 113.3 135.9 109.8 134.2 104.6 - 117.7 100.9 114.1 - -

All numbers in USD currency

Quarterly Financial Ratios USANA Health Sciences

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 0.52 0.41 - -0.36 0.52 0.49 - 0.56 0.55 0.86 - 0.59 0.89 0.95 - 0.78 1 1.16 - 1.37 1.89 1.47 - 1.45 1.33 1.24 1.42 1.09 0.92 1.03 1.35 1.28 1.4 1.2 -0.24 0.98 0.95 0.87 0.9 1.24 1.08 0.92 1.75 1 1 0.78 - 1.51 1.4 1.19 1.46 1.22 1.79 1.3 1.3 1.22 1.14 0.92 0.88 0.82 0.89 0.71

EBITDA per Share

 1.32 1.2 - 0.5 1.32 1.26 - 1 1.14 1.45 - - - 1.56 - 1.7 1.87 1.88 - 2.53 2.97 2.27 - 2.16 1.88 1.98 - 2.1 1.67 1.66 - 2.4 2.47 1.98 - 1.78 1.63 1.48 - 1.89 1.85 1.53 - 3.52 3.41 2.54 - 2.79 2.43 1.96 - 2.3 3.04 2.12 - 2.14 2.01 1.54 - 1.67 1.64 1.22

ROE %

 3.93 3.74 2.36 4.35 7.62 9.11 7.33 9.75 11.44 13.45 10.14 13.77 16.10 18.18 14.14 20.99 26.49 29.35 23.58 31.42 32.59 31.82 24.21 32.96 32.01 30.07 28.58 28.10 29.15 31.74 32.27 22.39 21.00 18.74 17.22 25.56 28.26 29.78 30.75 33.28 32.20 33.21 34.13 34.65 34.07 31.05 23.28 31.06 27.72 29.42 30.33 32.49 35.48 35.21 35.80 33.43 31.12 30.07 29.18 7.12 7.97 6.53

ROA %

 2.84 2.69 1.68 3.26 5.81 7.12 5.86 7.75 9.04 10.42 7.79 10.48 12.02 13.08 10.04 14.76 18.54 20.35 16.42 21.71 22.45 21.59 16.35 22.30 21.70 20.38 19.45 19.33 20.24 22.22 22.77 15.81 14.79 13.15 12.04 17.82 19.64 20.63 21.26 22.68 22.12 22.87 23.38 23.46 23.06 21.29 16.04 21.55 19.94 21.07 21.45 22.84 24.84 24.53 24.85 23.33 21.85 21.26 20.76 5.07 5.67 4.64

ROCE %

 9.07 8.89 6.34 9.26 12.52 14.30 11.34 15.09 17.37 19.78 14.84 20.35 23.88 27.15 21.26 31.48 38.80 42.50 34.02 45.68 46.80 46.25 35.28 45.36 42.56 41.18 28.89 40.53 43.52 45.69 35.74 44.37 41.65 37.63 26.60 37.62 40.49 41.88 32.83 44.94 47.55 47.80 37.50 52.17 51.49 46.85 35.09 44.57 43.89 42.65 33.67 46.64 50.72 47.97 37.77 48.57 47.76 44.11 32.87 10.80 12.16 9.91

Current Ratio

 4.7 5.1 4.6 5.0 4.9 4.6 4.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

 2.7 1.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

 180.9 127.5 - 162.7 142.6 124.7 - 146.2 138.8 129.6 - 130.9 133.2 123.7 - 148.4 167.5 173.9 - 167.2 141.8 69.4 - 119.4 124.3 128.2 - 131.5 135.2 149.9 - 144.1 149.6 133.9 - 121.8 - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

 30.4 21.7 - 31.9 29.0 22.6 - 15.9 16.9 19.4 - 19.9 20.8 20.3 - 20.1 19.7 26.1 - 24.2 20.1 9.5 - 20.3 21.8 24.1 - 23.9 24.6 22.3 - 17.5 18.2 20.1 - 22.8 - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

 - - - 162.7 142.6 124.7 - 146.2 138.8 129.6 - 130.9 133.2 123.7 - 148.4 167.5 173.9 - 167.2 141.8 69.4 - 119.4 124.3 128.2 - 131.5 135.2 149.9 - 144.1 149.6 133.9 - 121.8 - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

 - - - 130.8 113.6 102.1 - 130.3 121.9 110.2 - 111.0 112.3 103.5 - 128.3 147.7 147.8 - 143.1 121.8 59.9 - 99.0 102.5 104.1 - 107.6 110.7 127.6 - 126.6 131.4 113.8 - 99.0 - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company USANA Health Sciences, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Household products industry

Issuer Price % 24h Market Cap Country
Coty Coty
COTY
 		$ 3.05 -5.13 % $ 2.68 B usaUSA
Dogness (International) Corporation Dogness (International) Corporation
DOGZ
 		$ 0.77 5.11 % $ 13.7 M chinaChina
e.l.f. Beauty e.l.f. Beauty
ELF
 		$ 113.78 -0.84 % $ 6.63 B usaUSA
Edgewell Personal Care Company Edgewell Personal Care Company
EPC
 		$ 26.98 -4.39 % $ 1.28 B usaUSA
Acme United Corporation Acme United Corporation
ACU
 		$ 63.2 -0.6 % $ 239 M usaUSA
Revlon Revlon
REV
 		- -4.41 % $ 212 M usaUSA
Mannatech, Incorporated Mannatech, Incorporated
MTEX
 		$ 8.51 4.29 % $ 16.2 M usaUSA
Colgate-Palmolive Company Colgate-Palmolive Company
CL
 		$ 93.4 -1.21 % $ 75.5 B usaUSA
Nature's Sunshine Products Nature's Sunshine Products
NATR
 		$ 12.26 -3.54 % $ 221 M usaUSA
Nu Skin Enterprises Nu Skin Enterprises
NUS
 		$ 4.76 -4.51 % $ 235 M usaUSA
Newell Brands Newell Brands
NWL
 		$ 5.56 -2.11 % $ 2.33 B usaUSA
Church & Dwight Co. Church & Dwight Co.
CHD
 		$ 105.0 -0.91 % $ 25.5 B usaUSA
The Procter & Gamble Company The Procter & Gamble Company
PG
 		$ 156.84 -1.61 % $ 366 B usaUSA
The Estée Lauder Companies The Estée Lauder Companies
EL
 		$ 103.66 -2.32 % $ 37.6 B usaUSA
United-Guardian United-Guardian
UG
 		$ 6.75 -0.15 % $ 31 M usaUSA
Unilever PLC Unilever PLC
UL
 		$ 64.4 -1.26 % $ 141 B britainBritain
Hims & Hers Health Hims & Hers Health
HIMS
 		$ 29.21 -0.31 % $ 6.57 B usaUSA
LifeVantage Corporation LifeVantage Corporation
LFVN
 		$ 5.95 -0.34 % $ 74.6 M usaUSA
Inter Parfums Inter Parfums
IPAR
 		$ 113.2 -2.33 % $ 3.63 B usaUSA
Helen of Troy Limited Helen of Troy Limited
HELE
 		$ 28.38 -3.54 % $ 653 M bermudaBermuda
Spectrum Brands Holdings Spectrum Brands Holdings
SPB
 		$ 78.96 -0.7 % $ 2.03 B usaUSA
The Clorox Company The Clorox Company
CLX
 		$ 84.77 -3.05 % $ 10.5 B usaUSA
Kimberly-Clark Corporation Kimberly-Clark Corporation
KMB
 		$ 106.64 -1.56 % $ 35.4 B usaUSA
Natura &Co Holding S.A. Natura &Co Holding S.A.
NTCO
 		- - $ 9.02 B -